Lee A Dawson Selected Research

Schizophrenia (Dementia Praecox)

1/2017	Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator.
9/2013	Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
2/2010	In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
1/2010	Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia.
5/2009	Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR.
2/2009	alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex.
2/2009	Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412).
1/2009	Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
1/2009	Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.
6/2008	In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lee A Dawson Research Topics

Disease

14	Schizophrenia (Dementia Praecox) 01/2017 - 03/2005
4	Alzheimer Disease (Alzheimer's Disease) 05/2024 - 11/2003
4	Mental Disorders (Mental Disorder) 01/2024 - 02/2004
4	Mood Disorders (Mood Disorder) 01/2009 - 06/2006
3	Catalepsy 01/2021 - 01/2007
3	Inflammation (Inflammations) 01/2020 - 01/2017
3	Memory Disorders (Memory Loss) 11/2009 - 04/2008
3	Cognitive Dysfunction 04/2008 - 02/2004
2	Neuroinflammatory Diseases 02/2024 - 01/2023
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 01/2020
2	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2021
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 02/2009 - 12/2008
2	Polydipsia 05/2008 - 11/2007
2	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 05/2008 - 11/2007
1	Sleep Wake Disorders 01/2024
1	Movement Disorders (Movement Disorder) 01/2023
1	Major Depressive Disorder (Major Depressive Disorders) 12/2013
1	Mania (Manias) 09/2011
1	Neurobehavioral Manifestations 01/2010
1	Psychotic Disorders (Schizoaffective Disorder) 01/2009
1	Substance-Related Disorders (Drug Abuse) 12/2008
1	Anxiety Disorders (Anxiety Disorder) 01/2008
1	Dementia (Dementias) 06/2007
1	Hypothermia 06/2006
1	Amyloid Plaque 11/2003

Drug/Important Bio-Agent (IBA)

4	Dopamine (Intropin)FDA LinkGeneric 01/2023 - 12/2008
4	Antipsychotic Agents (Antipsychotics)IBA 09/2013 - 01/2007
3	InflammasomesIBA 02/2024 - 01/2018
3	Neurokinin-3 ReceptorsIBA 02/2010 - 01/2008
3	Serotonin (5 Hydroxytryptamine)IBA 04/2008 - 05/2007
2	Ion Channels (Ion Channel)IBA 05/2024 - 11/2007
2	Haloperidol (Haldol)FDA LinkGeneric 01/2021 - 01/2009
2	LipopolysaccharidesIBA 01/2020 - 01/2017
2	Antidepressive Agents (Antidepressants)IBA 12/2013 - 01/2008
2	Vilazodone HydrochlorideIBA 12/2013 - 01/2009
2	LigandsIBA 09/2013 - 01/2010
2	Histamine H3 Receptors (Histamine H3 Receptor)IBA 01/2009 - 06/2007
2	serotonin 6 receptorIBA 12/2006 - 02/2004
1	PotassiumIBA 05/2024
1	Adenosine Triphosphate (ATP)IBA 02/2024
1	Orexin ReceptorsIBA 01/2024
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Oxidopamine (6 Hydroxydopamine)IBA 01/2021
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Protein Kinases (Protein Kinase)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	AMPA Receptors (AMPA Receptor)IBA 01/2017
1	EpitopesIBA 01/2017
1	Glycogen Synthase (Synthase I)IBA 09/2011
1	GSK256471IBA 02/2010
1	3-amino-N-(cyclopropyl (phenyl)methyl)- 2- (3- fluorophenyl)- 4- quinolinecarboxamideIBA 02/2010
1	TachykininsIBA 02/2010
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2010
1	Fluoxetine (Prozac)FDA LinkGeneric 11/2009
1	Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)IBA 05/2009
1	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 05/2009
1	Fumigant 93 (D-D)IBA 05/2009
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2009
1	Dopamine D2 Receptor AntagonistsIBA 01/2009
1	5- ((3- cyclobutyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepin- 7- yl)oxy)- N- methyl- 2- pyrazinecarboxamideIBA 01/2009
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2009
1	ProlactinIBA 01/2009
1	Serotonin Receptor Agonists (Serotonin Receptor Agonist)IBA 01/2009
1	5-HT1A Serotonin ReceptorIBA 01/2009
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 12/2008
1	Peptides (Polypeptides)IBA 06/2008
1	SB 223412IBA 06/2008
1	N(1)- (6- chloroimidazo(2,1- b)(1,3)thiazole- 5- sulfonyl)tryptamineIBA 05/2008
1	Scopolamine (Hyoscine)FDA Link 04/2008
1	5-HT1 Serotonin ReceptorsIBA 01/2008
1	gamma-Aminobutyric Acid (GABA)IBA 11/2007
1	6- ((3- cyclobutyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepin- 7- yl)oxy)- N- methyl- 3- pyridinecarboxamideIBA 06/2007
1	AutoreceptorsIBA 05/2007
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 05/2007
1	indoleIBA 01/2007
1	Clozapine (Clozaril)FDA LinkGeneric 01/2007
1	1,2,3,4,8,9,10,10a- octahydro- 7bH- cyclopenta(b)(1,4)diazepino(6,7,1hj)indoleIBA 01/2007
1	Apomorphine FDA Link 01/2007
1	SB-616234-AIBA 06/2006
1	5-HT1B Serotonin ReceptorIBA 06/2006
1	Lysophosphatidic Acid ReceptorsIBA 03/2005
1	EnzymesIBA 11/2003

Therapy/Procedure

4	Therapeutics 01/2010 - 06/2006
1	Oral Administration 01/2021